Shilpa Medicare is scaling formulations, biologics, peptides and CDMO alongside its core API business, with Q1FY27 revenue and profit reaching record levels. After a 238% gain in 2026, the focus is shifting to whether its pipeline and new capacity can sustain earnings growth.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.